Special Issue "20th Anniversary of Pharmaceuticals–Drug Design and Pharmacological Advances in Neurodegenerative Disease"
Deadline for manuscript submissions: 15 March 2024 | Viewed by 1699
Interests: medicinal chemistry; drug design; GPCR; enzyme; neuroprotective agents, cystic fibrosis; QSAR; virtual screening; homology modeling
Special Issues, Collections and Topics in MDPI journals
Special Issue in Molecules: Virtual Screening in Modern Medicinal Chemistry
Special Issue in Pharmaceuticals: Cystic Fibrosis and Rare Mutations: New Promising Approaches via Proteostase Modulators
Nowadays, human life expectancy is increasing, thus leading to population aging being inevitable and often accompanied by increased levels of patients developing neurodegenerative diseases. Neuroprotection represents an intriguing strategic approach to contrast neurodegeneration as shown in a variety of central nervous system (CNS) disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and drug misuse-induced neurotoxicity, among others. Recently, novel therapeutic agents for neurodegenerative diseases based on small molecules as well as unprecedented druggable targets mediating a neuroprotective effect have been investigated. This Special Issue invites both reviews and original articles that shed light on the state of the art and on the latest findings in the search for novel drug-like neuroprotective agents, and aims to elucidate future directions probing promising biological targets such as GPCRs or enzymes. The rational design and development of new neuroprotective compounds based on virtual screening applications and high-throughput screening (HTS) campaigns are also included in the scope of this Special Issue.
Dr. Elena Cichero
Dr. Michele Tonelli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neuroprotective agents
- chemical synthesis
- drug design